Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Relationships of High-Sensitivity C-Reactive Protein and Homocysteine Levels With Disease Activity, Damage Accrual, and Cardiovascular Risk in Systemic Lupus Erythematosus.
|
31763930 |
2020 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly, the combination of nCD64 index, CRP, WBC, C3 and C4 improved significantly the diagnostic potential of SLE infection (AUC 0.783 (interquartile range 0.672, 0.871), p < 0.001; sensitivity 85.29% specificity 62.50%).
|
30712491 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Autoantibodies against mCRP are frequently detected in systemic lupus erythematosus (SLE) and associated with disease activity and prognosis.
|
30539580 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CGCG haplotype was significantly more common in SLE than in HSs. rs4945 was associated with the erythrocyte sedimentation rate and rs1878327 was associated with alopecia, C-reactive protein, complement 3, anti-dsDNA antibody, and high disease activity. rs2271715 and rs3743388 were associated with renal disease, cumulative glucocorticoid dose, and cyclophosphamide and mycophenolate mofetil use.
|
31811237 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erythrocyte sedimentation rate and C-reactive protein were elevated, an autoimmune workup was consistent with a new diagnosis of systemic lupus erythematosus and triple-positive antiphospholipid antibodies.
|
31092489 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Utility of neutrophil-to-lymphocyte ratio plus C-reactive protein for infection in systemic lupus erythematosus.
|
30661452 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The human miR-34a, increased in peripheral blood mononuclear cells (PBMCs) and CD4<sup>+</sup> T cells from rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) patients, displayed a positive correlation with some serum markers of inflammation including rheumatoid factor (RF), anti-streptolysin antibody (ASO), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as well as Th17 signature gene RORγt, but inversely correlated with the mRNA expression levels of FOXP3.
|
31130368 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-reactive protein (CRP) is a better marker for infections than for SLE activity, where there is only a limited association, and procalcitonin (PCT) is also mainly used for detecting severe bacterial infection.
|
31812331 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mild elevations of CRP have been seen in chronic autoimmune diseases like systemic lupus erythematosus (SLE), and CRP has been linked to an increased risk of cardiovascular events.
|
30282476 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among clinical parameters, concentrations of C3/C4 were lower and erythrocyte sedimentation rate, C-reactive protein, anti-double-stranded DNA (anti-dsDNA) antibodies, and SLE Disease Activity Index-2000 (SLEDAI-2K) were higher in LN patients than in SLE patients without LN.
|
30941928 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In comparison with non-infectious SLE patients (387.9±261.6/μL), CD4+T cells count decreased significantly in infectious SLE patients (217.8±150.4/μL) (P<0.05), and it was negatively correlated with infection-related indicators including PCT (r=-0.573, P=0.041) and CRP (r=-0.596, P=0.032) levels.
|
30994732 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hs-CRP levels among active SLE were significantly higher (13.5+ 11.4 mg/L) as compared with inactive SLE (4.4 + 2.9 mg/L) (P=0.0002).
|
27531690 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the presence of anti-chloride intracellular channel 2 (anti-CLIC2) and anti-high mobility group box 1 (anti-HMGB1) autoantibodies in SLE patients (n = 43) versus healthy controls ([HCs] n = 43), and their association with serological parameters (antinuclear antibody [ANA], anti-double-stranded DNA [anti-dsDNA], and C-reactive protein [CRP]) and disease activity using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (active or inactive).
|
28862243 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Procalcitonin and C-reactive protein as markers of infection in systemic lupus erythematosus: the controversy continues.
|
29779437 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Factors, such as enlarged liver, spleen and lymph nodes, digestive system involvement, low hemoglobin, leukopenia, CRP, decreased albumin, anti-dsDNA antibody, glucocorticoids, and cyclophosphamide, were independent risk factors for noninfectious fever in SLE.
|
30847312 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis showed that CRP (>24.0 mg/L) was the only independent risk factor for SLE infection (odds ratio, OR = 2.896, P = .032).
|
31415387 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The relationship between anti-C-reactive protein and disease activity in patients with systemic lupus erythematosus.
|
28352058 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, monotherapy with HCQ for three months significantly reduced PCSK9 and CRP levels in inactive SLE patients.
|
30603640 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Conclusions The ratio of ESR:CRP may provide diagnostic value beyond individual ESR and CRP levels in distinguishing flare vs infection in SLE patients presenting with fever.
|
29546774 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to characterize pharmacokinetics (PK) of PF-04236921, a novel anti-interleukin-6 monoclonal antibody, and its pharmacokinetic/pharmacodynamic (PK/PD) relationship on serum C-reactive protein (CRP) in healthy volunteers and patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Crohn's disease (CD).
|
29776017 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Importantly, RIPK1 expression in neutrophils negatively correlated with ESR, CRP, 24-hour urine total protein, and the disease activity index in SLE.
|
29550813 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
NLR was positively correlated with the SLE Disease Activity Index 2000 (SLEDAI-2K), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), whereas it was not correlated with C3 or C4.
|
30112073 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with CNS infections also had a larger prednisone dose at the time of symptom onset, larger cumulative dosages over the preceding year, lower SLE Disease Activity Index (SLEDAI) scores, higher rate of nephritis, lower albumin levels, higher C-reactive protein (CRP) levels, higher 24-h-urine protein levels, higher cerebrospinal fluid (CSF) white blood cell levels, and lower protein and glucose levels than those with NPSLE.
|
28823196 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
When an SLE patient presents with pre-existing arthritis and suddenly develops asymmetric oligo- or large-joint swelling and pain with elevated CRP levels and low disease activity, joint infections should be considered.
|
28688058 |
2017 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elevated levels of Sema5A were correlated positively with 24-h proteinuria excretion (r = 0·558, P < 0·0001), SLE disease activity index (SLEDAI) (r = 0·278, P = 0·0006) and C-reactive protein (CRP) (r = 0·266, P = 0·002), but negatively with planet (PLT) (r = -0·294, P = 0·0003) and complement 3 (C3) (r = -0·287, P = 0·0004) in SLE patients.
|
28063160 |
2017 |